Researchers at The University of Nottingham have taken some important first steps to creating a synthetic copycat of a living cell, a leading science journal reports.Dr Cameron Alexander and PhD student George Pasparakis in the University’s School of Pharmacy have used polymers - long-chain molecules - to construct capsule-like structures that have properties mimicking the […]

A drug used to strengthen the bones of women with breast cancer helped cut the risk of the cancer returning by 36 percent, European researchers said on Saturday,
Full Story

The Associated Press Saturday, May 31, 2008; 10:01 AM CHICAGO — A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left …
Full Story

British scientists from the Peninsula Medical School say they’ve modified a photodynamic treatment that’s designed to destroy cancer cells.
Full Story

Head and neck cancer patients who reported lower physical quality of life were more likely to die from their disease, according to a new study from the University of Michigan Comprehensive Cancer Center. The findings could mean that identifying patients with poor quality of life could also identify patients with particularly aggressive tumors.”Low quality of […]

The gene that allows fireflies to flash is helping researchers track the effectiveness of anti-cancer drugs over time.UT Southwestern Medical Center researchers are among the first to show that a technique called bioluminescence imaging (BLI) can be used to determine the effectiveness of cancer drugs that choke off a tumor’s blood supply.The technique requires a […]

GenVec, Inc. (Nasdaq:GNVC) presented an overview of TNFeradeâ„¢ development and an update on long-term survival data from its Phase II clinical trial using TNFerade in patients with esophageal cancer at the American Society of Gene Therapy (ASGT) 11th Annual Meeting in Boston, MA. Dr.
Full Story

Schering-Plough Corporation (NYSE: SGP) announced that about 80 posters, poster discussions, and oral presentations from about 60 clinical studies relating to its growing oncology franchise will be presented at the upcoming 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - June 3.
Full Story

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the initiation of the INTORACT (INvestigation of TORISEL and Avastin Combination Therapy) study, a worldwide randomized, open-label, phase 3b study comparing TORISEL(R) (temsirolimus) plus Avastin(R) (bevacizumab) versus Avastin plus interferon-alfa for first-line treatment of patients with advanced renal cell carcinoma (RCC).
Full Story

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced solid tumors.
Full Story